Department of Ophthalmology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.
Biomed Res Int. 2013;2013:585729. doi: 10.1155/2013/585729. Epub 2013 Nov 12.
To assess the long-term effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP).
Patients with RP were randomly divided into a treated group receiving oral nilvadipine and a control group. Progression of RP was evaluated with MD slope and the average sensitivity of the central 2° (ΔCENT4).
The mean MD slopes were -0.55/-0.39 (right/left eyes, n = 19) dB/year in the treated group and -1.37/-1.15 (right/left eyes, n = 22) dB/year in the control group (P = 0.016/0.050, resp.). In both eyes, however, no statistical difference was observed between the two groups for the ΔCENT4 values.
Although we confirmed that nilvadipine significantly retarded the progression of the average of MD value defects in the central 10°, it was not specific for the central 2° of the visual field in RP.
评估尼伐地平对视网膜色素变性（RP）中心视野缺损进展的长期影响。
将 RP 患者随机分为接受尼伐地平口服治疗的治疗组和对照组。用 MD 斜率和中央 2°平均敏感度（ΔCENT4）评估 RP 的进展情况。
治疗组的平均 MD 斜率分别为 -0.55/-0.39（右眼/左眼，n = 19）dB/年和 -1.37/-1.15（右眼/左眼，n = 22）dB/年（P = 0.016/0.050，分别）。然而，两组在双眼的 ΔCENT4 值方面均无统计学差异。
尽管我们证实尼伐地平显著延缓了中央 10°平均 MD 值缺陷的进展，但对 RP 中心 2°的视野并无特异性。
